These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2396858)

  • 1. Epoetin alfa: patient management issues and development through recombinant DNA technology. Part 2: Answers to questions about Epoetin alfa.
    Gallagher N; Latham D; Prowant B; Binkley L; Chapin R; Erlich L; Nichols E; Osborne D
    ANNA J; 1990 Aug; 17(4):314-6. PubMed ID: 2396858
    [No Abstract]   [Full Text] [Related]  

  • 2. Epoetin alfa: patient management issues and development through recombinant DNA technology. Part 1: Focus on Epoetin alfa patient management and recombinant DNA technology.
    Latham D; Nichols E
    ANNA J; 1990 Aug; 17(4):311-4. PubMed ID: 2396857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients.
    Washida N; Inoue S; Kasai T; Shinozuka K; Hosoya K; Morimoto K; Wakino S; Hayashi K; Itoh H
    Ther Apher Dial; 2015 Oct; 19(5):450-6. PubMed ID: 25944557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
    Garton JP; Gertz MA; Witzig TE; Greipp PR; Lust JA; Schroeder G; Kyle RA
    Arch Intern Med; 1995 Oct; 155(19):2069-74. PubMed ID: 7575066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case management of the anemic patient. Epoetin alfa: focus on kinetic dosing.
    Keen ML
    ANNA J; 1990 Aug; 17(4):318-9. PubMed ID: 2396859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability, potency, and preservative effectiveness of epoetin alfa after addition of a bacteriostatic diluent.
    Corbo DC; Suddith RL; Sharma B; Naso RB
    Am J Hosp Pharm; 1992 Jun; 49(6):1455-8. PubMed ID: 1529989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case management of the anemic patient. Focus on blood pressure and rHuEPO therapy.
    Holechek MJ; Watson AJ
    ANNA J; 1990 Feb; 17(1):72-3. PubMed ID: 2317107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case management of the anemic patient: epoetin alfa--focus on iron supplementation.
    Kirlin LF
    ANNA J; 1993 Dec; 20(6):678-81. PubMed ID: 8267412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human erythropoietin.
    Jones EH
    Am J Hosp Pharm; 1989 Nov; 46(11 Suppl 2):S20-3. PubMed ID: 2690606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case management of the anemic patient. Epoetin alfa: focus on inflammation and infection.
    Schardin KE
    ANNA J; 1990 Dec; 17(6):468-9. PubMed ID: 2256731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic value of iron indices in hemodialysis patients receiving epoetin.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA;
    Kidney Int; 2001 Jul; 60(1):300-8. PubMed ID: 11422765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome.
    Patton JF; Sullivan T; Mun Y; Reeves T; Rossi G; Wallace JF
    J Support Oncol; 2005; 3(6):419-26. PubMed ID: 16350429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy.
    Demetri GD; Gabrilove JL; Blasi MV; Hill RJ; Glaspy J
    Clin Breast Cancer; 2002 Apr; 3(1):45-51. PubMed ID: 12020395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controversies in determination of epoetin (recombinant human erythropoietin) dosages.
    Abraham PA; St Peter WL; Redic-Kill KA; Halstenson CE
    Clin Pharmacokinet; 1992 Jun; 22(6):409-15. PubMed ID: 1587054
    [No Abstract]   [Full Text] [Related]  

  • 16. Epoetin alfa: patient management.
    ANNA J; 1989 Aug; 16(5):348-50. PubMed ID: 2774689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable erythroid response after discontinuation of epoetin-alpha: an unexpected outcome in a patient with myelodysplastic syndrome.
    Niscola P; Giovannini M; Tendas A; Scaramucci L; Perrotti A; De Fabritiis P
    Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s160-1. PubMed ID: 23522884
    [No Abstract]   [Full Text] [Related]  

  • 18. Case management of the anemic patient. Epoetin alfa: focus on iron management.
    Kirlin LF
    ANNA J; 1990 Jun; 17(3):256-7. PubMed ID: 2357123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of patients' responses to epoetin alfa therapy.
    Krantz SB
    Pharmacotherapy; 1990; 10(2 ( Pt 2)):15S-21S. PubMed ID: 2189124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
    Moreno de Gusmão B; Guinea de Castro JM; Perez-Persona E; Oiartzabal I
    Med Clin (Barc); 2014 Jan; 142(2):91-2. PubMed ID: 23790532
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.